126926-42-9

Basic information

• Product Name: methyl 3-(dipropylcarbamoyl)benzoate
• Synonyms: Benzoic acid, 3-((dipropylamino)carbonyl)-, methyl ester; Methyl 3-((dipropylamino)carbonyl)benzoate
• CAS NO: 126926-42-9
• Molecular Formula: C₁₅H₂₁NO₃
• Molecular Weight: 263.3321
• Mol File: 126926-42-9.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 404.9°C at 760 mmHg
• Flash Point: 198.7°C
• Density: 1.059g/cm³
• Vapor Pressure: 9.11E-07mmHg at 25°C
• Refractive Index: 1.514
• CAS DataBase Reference: methyl 3-(dipropylcarbamoyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-(dipropylcarbamoyl)benzoate(126926-42-9)
• EPA Substance Registry System: methyl 3-(dipropylcarbamoyl)benzoate(126926-42-9)

Safety Data

• Hazardous Substances Data: 126926-42-9(Hazardous Substances Data)

Upstream product

• 142-84-7 di-n-propylamine 
• 3441-03-0 3-(methoxycarbonyl)benzoyl chloride 
• 121-91-5 isophthalic acid 
• 1459-93-4 dimethyl Isophthalate 
• 1877-71-0 benzene 1,3-dicarboxylic acid monomethyl ester 

Downstream Products

• 1203560-43-3 C₃₅H₄₇N₃O₆S 
• 126926-35-0 N,N-Dipropylisophthalamic acid 

Relevant articles and documents

Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D

Following up the open initiative of anti-malarial drug discovery, a GlaxoSmithKline (GSK) phenotypic screening hit was developed to generate hydroxyethylamine based plasmepsin (Plm) inhibitors exhibiting growth inhibition of the malaria parasite Plasmodium falciparum at nanomolar concentrations. Lead optimization studies were performed with the aim of improving Plm inhibition selectivity versus the related human aspartic protease cathepsin D (Cat D). Optimization studies were performed using Plm IV as a readily accessible model protein, the inhibition of which correlates with anti-malarial activity. Guided by sequence alignment of Plms and Cat D, selectivity-inducing structural motifs were modified in the S3 and S4 sub-pocket occupying substituents of the hydroxyethylamine inhibitors. This resulted in potent anti-malarials with an up to 50-fold Plm IV/Cat D selectivity factor. More detailed investigation of the mechanism of action of the selected compounds revealed that they inhibit maturation of the P. falciparum subtilisin-like protease SUB1, and also inhibit parasite egress from erythrocytes. Our results indicate that the anti-malarial activity of the compounds is linked to inhibition of the SUB1 maturase plasmepsin subtype Plm X.

Design and synthesis of potent and selective BACE-1 inhibitor

Highly potent BACE-1 protease inhibitors have been developed from an inhibitors containing a hydroxyethylene (HE) core displaying aryloxymethyl or benzyloxymethyl P1 side chain and a methoxy P1′ side chain. The target molecules were synthesized in good overall yields from chiral carbohydrate starting materials. The inhibitors show high BACE-1 potency and good, selectivity against cathepsin D, where the most potent inhibitor furnishes BACE-1 Ki ? 1 nM and displays > 1000-fold selectivity over cathepsin D.

Norstatines from Aldehydes by sequential organocatalytic α-amination and passerini reaction

The combination of the enantioselective, organocatalytic α-amination of aldehydes by diazodicarboxylates and the Passerini reaction provides rapid access to norstatine-based peptidomimetics. These intermediates were elaborated further by deprotection and cleavage of the N-N bond to provide useful building blocks for aspartic protease inhibitors. Coupling of the compounds 76-86 with the mono-isophthalamide 91 provided moderate inhibitors of human β-secretase (BACE) 92-102. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.